Modern treatment strategies for superior vena cava syndrome
Superior vena cava syndrome (SVC syndrome) is a rare but serious condition caused by obstruction of venous blood flow from the brachiocephalic vein and superior vena cava back to the heart. Lung cancer is the most common malignant cause; while central venous thrombosis caused by venous catheters, pacemaker leads, and mediastinal fibrosis are common benign causes.
Background
Superior vena cava syndrome (SVC syndrome) occurs due to mechanical obstruction of the superior vena cava or bilateral brachiocephalic veins. Lung cancer is the most common cause of malignant SVC syndrome, followed by non-Hodgkin’s lymphoma and metastatic lesions of other malignancies. Benign superior vena cava and brachiocephalic vein obstruction has diverse causes, including central venous catheter placement, pacemaker or defibrillator implantation, mediastinal fibrosis, thrombotic tendency, granulomatous fungal infection, mediastinal radiotherapy, substernal goiter, aortic arch aneurysm, or aortic dissection.
Due to obstruction of the central venous outflow tract, patients often experience disabling symptoms related to head and neck congestion. Over the past few decades, treatment strategies for SVC syndrome have continuously evolved at our hospital and other institutions. Current treatment options include conservative treatment, radiotherapy and chemotherapy for malignant tumors, anticoagulation therapy, thrombolytic therapy, surgical reconstruction, and endovascular therapy, with bare-metal stents or covered stents being the most commonly used. For symptomatic patients, endovascular therapy has become the preferred first-line standard treatment. This article briefly describes the clinical manifestations and current assessment methods for these patients, updates existing treatment strategies, and focuses on venous stent placement for patients with benign or malignant SVC syndrome.
Materials and Methods
This review follows the Priority Reporting Items (PRISMA) guidelines for systematic reviews and meta-analyses within its scope. A systematic literature search was conducted using PubMed, MEDLINE, and Embase databases, including relevant studies evaluating endovascular and surgical treatment of superior vena cava syndrome from January 1990 to April 2025. Search terms were combinations of keywords and Medical Subject Headings (MeSH): “superior vena cava syndrome,” “superior vena cava obstruction,” “venous stent placement,” “balloon angioplasty,” “covered stent,” “open surgical reconstruction,” and “endovascular treatment.” Case series studies, systematic reviews, or meta-analyses were included; case reports with fewer than 5 patients and abstracts without full-text data were excluded. The review presents data on clinical presentation, intervention methods, stent characteristics, clinical and technical success rates, complications, and follow-up results in a narrative review format.
Clinical Presentation
Patients with superior vena cava and/or bilateral brachiocephalic vein obstruction present with clinical symptoms related to cerebral venous hypertension, including neurological, hemodynamic, and respiratory symptoms and signs. Patients may experience syncope, headache, dizziness, or confusion; swelling of the head and neck, upper limb edema, and dilation of neck and chest veins may also occur, accompanied by visual symptoms. Dyspnea and cough are the most common respiratory manifestations of SVC syndrome. In the advanced stages, patients cannot lie flat and require elevated pillows for sleep; bending over or tying shoelaces becomes difficult. Acute SVC syndrome is a life-threatening emergency, which can lead to impaired respiratory function, altered consciousness, and, in severe cases, coma. The Kishi scoring system is currently the most commonly used system for classifying the symptoms and signs of SVC syndrome.
Benign SVC syndrome is often caused by central venous catheters, pacemakers, or implantable cardioverter defibrillator (ICD) leads, mediastinal fibrosis, thrombotic tendency, or stenosis following radiotherapy. In contrast, malignant SVC syndrome is caused by external compression or direct invasion of the external vena cava by malignant tumors, most commonly lung cancer (especially small cell lung cancer), non-Hodgkin’s lymphoma, or metastatic mediastinal malignancies. Benign superior vena cava syndrome typically presents with a slow onset, with signs and symptoms gradually progressing over weeks to months; malignant SVC syndrome, on the other hand, can have an onset within days to weeks, with symptoms progressing much more rapidly. Typical symptoms of benign SVC syndrome include swelling of the face, neck, and upper limbs, facial flushing, and dyspnea, with visible dilated collateral veins. Symptoms are usually mild, rarely involving the airway or causing brain complications. Conversely, malignant SVC syndrome, in addition to the above symptoms, is often accompanied by more severe symptoms such as airway obstruction, wheezing, cerebral edema, syncope, and even coma.
Asymptomatic superior vena cava obstruction may become apparent after establishing arteriovenous access for hemodialysis, presenting with rapid swelling of the upper limbs and neck distension. If extensive venous collateral circulation is present, the severity of symptoms in chronic SVC syndrome may not be correlated with the degree of anatomical obstruction.
Assessment and Imaging
Initial assessment should focus on ruling out malignant causes through history taking, physical examination, laboratory tests, and imaging studies. Neck and upper limb venous Doppler ultrasound can suggest central venous obstruction, but computed tomography venography (CTV) and/or magnetic resonance venography (MRV) are the main imaging methods for diagnosing and determining the extent of central venous obstruction. Traditional contrast venography was once the gold standard, but now it is almost always performed simultaneously with endovenous interventional therapy. CTV is used for follow-up of patients with recurrent symptoms. Intravascular ultrasound (IVUS) can be used as an adjunct to venography during endovenous procedures. It can measure vessel diameter when vessel filling is poor or collateral blood flow obstructs the vessel, assist in assessing the affected length, and guide the selection of balloon and stent sizes. IVUS helps ensure adequate stent-vessel fit, prevents displacement and folding, and can differentiate between soft thrombi, fibrotic stenosis, or extrinsic compression.
Conservative Treatment
Lifestyle interventions are crucial for patients with mild symptoms. Patients should sleep with their heads elevated, avoid wearing tight or high-necked clothing, and avoid bending over. Diuretics help control early symptoms; therapeutic anticoagulation is effective for acute or subacute thrombosis, especially for patients with benign lesions. Radiotherapy and chemotherapy often relieve symptoms in patients with mediastinal malignancies.
Endovascular Treatment
For symptomatic patients, endovascular treatment has become the first-line treatment option. For some patients with benign lesions caused by central venous catheters, pacemaker leads, or implanted cardioverter defibrillator leads, angioplasty alone can achieve the therapeutic goal after removing the catheter or lead. Patients with acute or subacute SVC syndrome can achieve good results with anticoagulation, catheter-directed thrombolysis, or mechanical thrombectomy. Thrombus removal often exposes the underlying stenotic lesion. Endovascular treatment for chronic SVC syndrome includes balloon angioplasty and the placement of bare-metal or covered stents.
Superior vena cava stent placement technique
Endovascular intervention is usually performed under local anesthesia; general anesthesia is recommended for patients with severe symptoms to control the airway and manage the potentially severe pain that may occur during powerful balloon dilation of complex lesions. A 6–12F sheath is placed via ultrasound-guided puncture through the right internal jugular vein or an upper limb vein (basilic/brachial vein) and/or common femoral vein. Some researchers prefer the internal jugular vein or upper limb approach to avoid femoral vein puncture because patients with severe SVC syndrome experience prolonged bed rest and the consequences of thrombosis at the puncture site are more serious. Diagnostic venography can identify and confirm the stenosis or occlusion lesion causing central venous obstruction.
A 0.035-inch soft or rigid hydrophilic guidewire, along with a standard catheter, is used to pass through the obstructed superior vena cava or brachiocephalic vein. Short stenosis can be treated directly, while complex lesions require a guidewire insertion via the femoral vein. At this stage, intraatrial and proximal obstruction pressure measurements are performed.
Plantar-guided angioplasty (PTA) is performed using a standard 10–16 mm high-pressure angioplasty balloon. Due to elastic recoil, bare-metal stents or covered stents are routinely placed simultaneously.
Stents used for superior vena cava obstruction
The efficacy of venous stent placement is influenced by several key factors. An ideal venous stent should possess high radial support, resistance to compression and breakage, good flexibility, and minimal or no shortening upon deployment. The covered structure is particularly important for patients with malignant lesions, preventing tumor infiltration into the lumen and providing occlusion in the event of superior vena cava rupture, thus avoiding cardiac tamponade.
Over the past two decades, various stents have been used to treat SVC syndrome. Venous stents can be classified into braided, stainless steel braided, or laser-engraved self-expanding nickel-titanium alloy stents, and can also be classified into bare metal stents or polytetrafluoroethylene (PTFE) covered stents. In the United States, the Wallstent stent is the most commonly used stent in clinical venous stent placement, often in combination with Z-shaped stents. In recent years, several specialized venous stents have been developed, offering more precise positioning, stronger radial support, and good flexibility. Laser-engraved nickel-titanium stents have largely replaced stainless steel braided stents, but they are more prone to breakage at pressure points. Our hospital currently prefers to use covered stents for superior vena cava recanalization, primarily because they reduce the risk of cardiac tamponade in the event of superior vena cava rupture. A potential drawback of placing covered stents in the superior vena cava and one unilateral brachiocephalic vein is the potential blockage of the contralateral patent brachiocephalic vein or azygos vein. There are reports of bilateral brachiocephalic vein kissing stents or Y-branch stents, but unilateral reconstruction is usually sufficient to relieve head and neck swelling and venous congestion symptoms.
Stent placement results
In 97%–99% of patients, superior vena cava (SVC) obstruction symptoms improve rapidly after successful stent placement. A recent meta-analysis by Aung et al., including 54 studies and 2249 patients with benign and malignant SVC syndrome, showed a pooled clinical success rate of 96.8% and a 1-year stent patency rate exceeding 90%.
Mekary et al. reported 15 cases of lead-related SVC syndrome. Of these, 13 underwent transvenous lead removal (TLE), and 10 underwent sequential stent placement post-procedure. One patient experienced perforation and cardiac tamponade due to a bare-metal stent, which was successfully treated with a covered stent and pericardiocentesis. Of the 7 patients who underwent lead re-implantation, 2 experienced symptom recurrence. The current recommended approach for lead-related SVC syndrome is lead removal combined with angioplasty and stent placement; if lead re-implantation is necessary, close follow-up monitoring for symptomatic restenosis is required.
Few studies have compared the patency rates of different stents in benign SVC syndrome (Table 2). Although dedicated venous stents are highly effective in the iliofemoral vein, current evidence does not support their superiority in superior vena cava stent placement. Matthaiou et al. included 156 patients with malignant SVC syndrome who underwent endovascular treatment via an upper limb approach, comparing the efficacy of dedicated venous stents (Sinus-XL stent) with conventional nickel-titanium alloy stents (E-Luminexx vascular stent, Protégé GPS stent). Four patients (9%) underwent only angioplasty, and 40 patients (91%) required stent implantation; one patient died during stent implantation due to cardiac tamponade. The primary patency rates at 1, 6, and 12 months were 94.5%, 84.8%, and 79.6%, respectively. There were no differences in patency rates between dedicated and non-dedicated venous stents, or between different Stanford SVC syndrome classification groups. Overall, there is no evidence that dedicated venous stents are superior to conventional stents in the treatment of malignant SVC syndrome. With one exception, all patients achieved technical and clinical success. The mean clinical follow-up was 1275 days, with 9 patients experiencing at least one symptom recurrence after a mean of 385 days. Four minor complications and two serious complications were reported.
A retrospective study of stent placement for benign SVC syndrome conducted by Haddad et al. at the Mayo Clinic compared the efficacy of 17 patients with covered stents with 30 patients with uncovered stents. Results showed that patients using Gore Viabahn or iCast covered stents had a significantly lower symptom recurrence rate at the last follow-up than those using Wallstent, Protégé, or SMART uncovered stents (29.4% vs 60%, P=0.044); the mean restenosis was also more severe in the uncovered stent group (48.3% vs 17.9%, P<0.001). Another study by Gwon et al. found that the 12-month patency rate of covered stents was 94%, compared to only 48% for uncovered stents. Our center’s current technical strategy prioritizes covered stent placement in the superior vena cava.
Complications of Superior Vena Cava Stent Placement
Superior vena cava stent placement is generally safe, but the risk of fatal complications is 1%–2%, with an overall complication rate of approximately 9%. Restenosis is the most common complication, while pericardial tamponade caused by stent perforation is the most serious. Because a segment of the superior vena cava is covered by the pericardium, rupture leading to cardiac tamponade can be life-threatening. Rapid diagnosis, prolonged balloon dilation, placement of a covered stent, and immediate ultrasound-guided pericardial drainage can save patients’ lives.
In a recent systematic review, the mean complication rate was 5.78%, and the reinjection rate was 9.11%. Another systematic review conducted by Azizi et al. involving 2200 patients showed a mean complication rate of 7.5% (95% CI 4.7%–10.3%), a restenosis rate of 10.5% (95% CI 8.4–12.6), and a symptom recurrence rate of 10.8% (95% CI 8.1–13.5). Stent fracture and displacement were more common in first-generation stents, but are now extremely rare with the preferred use of dedicated venous stents or covered stents. There are also reports of phrenic nerve paralysis occurring after using a 20×60mm Sinus SL stent and expanding it only to 12mm.
Other complications include infection, fever, cellulitis or hematoma at the puncture site, pulmonary embolism, and hemorrhage. Patients experiencing symptom recurrence due to restenosis, thrombosis, tumor invasion, or compression from surrounding inflammatory masses can usually undergo successful repeat endovascular intervention with excellent clinical outcomes. Some patients with mediastinal fibrosis or invasive tumors require multiple re-interventions due to repeated stent compression. The efficacy of dedicated venous stents, paclitaxel-coated balloons, or drug-eluting stents for the iliofemoral vein has not yet been studied in patients with SVC syndrome.
Post-stent placement anticoagulation therapy
Post-stent placement anticoagulation/antiplatelet regimens vary depending on the cause of the disease and also on the stent type, length, and the operator’s habits. Patients with acute/subacute thrombosis require oral anticoagulation for 3–6 months until the stent achieves pseudointimatting and the risk of rethrombosis decreases. Patients with mediastinal fibrosis may only use antiplatelet therapy (aspirin/clopidogrel). A long-term anticoagulation study conducted by Hahhad et al. at the Mayo Clinic on 58 patients who underwent stent placement for benign SVC syndrome showed no significant difference in restenosis rate or symptom recurrence rate with or without anticoagulation therapy.
Another important role of endovenous intervention is the re-intervention for restenosis. Whether endovascular repair or open surgical repair, a second intervention is required to maintain patency. Patients who initially received endovascular treatment continue to require re-intervention; while for patients who underwent surgical repair, the need for re-intervention generally decreases after 24–36 months. For in-stent restenosis, laser-assisted venous thrombectomy, as well as aspiration or pharmacodynamic thrombectomy, can be selected. Future research should focus on identifying the optimal stent materials and structures for SVC syndrome, especially endovascular reconstruction at the bifurcation of the superior vena cava and brachiocephalic vein. Given the difference in diameter between the superior vena cava and central veins, and the clear advantages of covered structures, the design of variable-diameter, flexible, and compression-resistant stents should be considered, along with selectable, securely fixed branch stents and localized central covered structures.
Superior vena cava occlusion: Open surgical treatment
Malignant SVC syndrome is rarely treated with open surgery, as it is mostly caused by mediastinal metastatic tumors. For benign SVC syndrome, open surgical reconstruction is considered only for symptomatic patients who are unsuitable for endovascular treatment or who have failed previous stent placement and endovascular re-intervention. Currently, almost all such patients have extensive type IV central venous obstruction. The technical and clinical success rate of open superior vena cava reconstruction is 93%–100%. Mayo Clinic case series show that the 5-year primary patency rate, auxiliary primary patency rate, and secondary patency rate for surgical bypass using spiral vein grafts or ePTFE grafts are 45%, 68%, and 75%, respectively. The auxiliary primary patency rate of vein grafts is higher than that of ePTFE grafts. If available, the femoral vein is an excellent graft material with durable patency. It is recommended to perform clinical and imaging monitoring every 6 months using Doppler ultrasound, CTV, or MRV during the first 2 years, followed by annual follow-up or timely follow-up when symptoms recur, as restenosis is usually accompanied by symptom recurrence.
Conclusion
Stent placement is a safe and effective first-line treatment for symptomatic SVC syndrome caused by benign or malignant etiologies. Using covered stents may achieve better efficacy and fewer complications.